Mapping of the binding surface between EPHA5 and antagonist peptide by NMR spectroscopy by ZHU WANLONG
MAPPING OF THE BINDING SURFACE BETWEEN 
EPHA5 AND ANTAGONIST PEPTIDE BY NMR 
SPECTROSCOPY 
 
                                  
 









MAPPING OF THE BINDING SURFACE BETWEEN 










A THESIS SUBMITTED FOR THE DEGREE OF 
MASTER OF SCIENCE 
DEPARTMENT OF BIOLOGICAL SCIENCES 







I would very much like to express my sincere appreciation to my supervisor, 
Associate Professor Song Jianxing for his support and experimental guidance thorough 
the duration of this study.  
I would like to give my special thanks to Ms. Qin Haina for her help in 
determining the structure of WDC by NMR, and to Dr. Shi Jiahai for his work in 
determining the structure of EphA5 by X-ray crystallography. 
I also want to thank Dr. Liu Jingxian, Ms. Huan Xuelu as well as all my lab mates 
for their valuable advices and help in this project. In addition, I am thankful to Dr. Fan 
Jingsong for all the NMR trainings and his kind assistance in NMR experiments.  
Especially, I would like to thank my parents for their strong and continuous 
support and encouragement for my study.  
Finally, I am grateful to the Ministry of Education of Singapore for the scholarship 
support and National University of Singapore for the excellent post-graduate programme 





Table of Contents 
ACKNOWLEDGEMENTS...............................................................................................I 
TABLE OF CONTENTS..................................................................................................II 
SUMMARY......................................................................................................................VI 
LIST OF FIGURES......................................................................................................VIII 
LIST OF TABLES............................................................................................................X 
LIST OF ABBREVIATIONS.........................................................................................XI 
APPENDIX....................................................................................................................XIII 
Chapter I INTRODUCTION...........................................................................................1 
   1.1 Introduction to Eph Receptors. ..............................................................................1 
         1.1.1 Biological background of Eph receptors.......................................................1 
         1.1.2 Structures of Eph receptors and the Eph receptor/ephrin complexes…...3 
                            1.1.3 Drug designs from structural insights of Eph receptors and ephrin 
ligands.................................................................................................9 
         1.1.4 Function of EphA5 receptor.........................................................................10 
    1.2 Structure Determination of Protein/Peptide.......................................................11 
         1.2.1 Introduction to NMR spectroscopy.............................................................12 
                 1.2.1.1 NMR....................................................................................................12  
                 1.2.1.2 NMR parameters................................................................................12   
                          1.2.1.2.1 Chemical shift.........................................................................12   
                          1.2.1.2.2 J coupling.................................................................................13 
                          1.2.1.2.3 NOE..........................................................................................14 
         1.2.2 Introduction to X-ray crystallography........................................................14 
III 
 
                  1.2.2.1 X-ray crystallography........................................................................14   
                  1.2.2.2 Solution to phase problem.................................................................15 
                        1.2.2.2.1 Direct methods..........................................................................15 
                        1.2.2.2.2 Multiple isomorphous replacement (MIR)............................16 
                        1.2.2.2.3 Anomalous scattering...............................................................16 
                        1.2.2.2.4 Molecular replacement (MR) .................................................17 
                  1.2.2.3 Refinement of initial model...............................................................17 
   1.3 Research Aims.........................................................................................................18 
Chapter II MATERIALS AND METHODS.................................................................19           
    2.1 Cloning of Proteins and/or Peptides.....................................................................19 
    2.2 Selection of Residues for Sit-directed Mutagenesis............................................20 
2.3 Transformation of E. coli Cells.............................................................................20 
2.4 Expression and Purification of EphA5 and Peptides...................................20 
        2.4.1 Expression and purification of the EphA5 ligand-binding domain...........20 
        2.4.2 Expression and purification of WDC and its mutants................................23 
        2.4.3 Preparation of isotope-labelled protein and/or peptides.............................23 
     2.5 Circular Dichroism (CD) Measurement ............................................................23 
     2.6 Crystallization of EphA5......................................................................................24   
     2.7 Characterization of the Binding of EphA5 with WDC and its Mutants by 
HSQC of NMR.....................................................................................................24 
     2.8 Characterization of the Binding of EphA5 with WDC and its Mutants by 
Isothermal Titration Calorimetry (ITC) ...........................................................25 
     2.9 NMR Experiments of EphA5 and WDC.............................................................25 
IV 
 
         2.9.1 Backbone assignment of EphA5...................................................................25 
         2.9.2 Structure determination of WDC by NMR.................................................26 
Chapter III EXPERIMENTAL RESULTS AND DISCUSSIONS............................27 
     3.1 Expression of EphA5 Ligand-Binding Domain.................................................27 
     3.2 Structural Characterization of EphA5 by CD...................................................27 
     3.3 Crystal Structure of EphA5 Ligand-Binding Domain......................................29 
     3.4 Structural Characterization of EphA5 by NMR...............................................29 
     3.5 Characterization of Binding Interactions between EphA5 and WDC Peptide 
by NMR.................................................................................................................32 
     3.6 Characterization of Binding Interactions between EphA5 and WDC Peptide 
by ITC...................................................................................................................35  
     3.7 Structural Characterization of WDC by CD......................................................38 
     3.8 Structural Characterization of WDC by NMR..................................................38 
     3.9 NMR Structure of WDC......................................................................................42 
     3.10 Mapping of Binding Interface between EphA5 and WDC by NMR.............46 
         3.10.1 Mapping of EphA5-binding interface within WDC by NMR and ITC..46 
              3.10.1.1 Interaction of WDC-mutant peptides with EphA5 by NMR……...46 
              3.10.1.2 Interaction of WDC-mutant peptides with EphA5 by ITC……….50       
              3.10.1.3 Structural comparison of WDC and its mutant peptides by CD…50 
          3.10.2 Mapping of EphA5-binding interface to WDC by NMR........................54 




               3.10.2.2 Mapping of EphA5-binding interface to WDC by chemical shift 
perturbation analysis.........................................................................58 
Chapter IV CONCLUSION AND FUTURE WORK.................................................61 







The Eph receptors constitute the largest family of receptor tyrosine kinases, with 
16 individual receptors that are activated by 9 different ephrins throughout the animal 
kingdom.  Eph receptors and their ligands are both anchored to the plasma membrane, 
and are subdivided into two subclasses (A and B) based on their sequence conservation 
and binding preferences. The critical roles of Eph-ephrin mediated signalling in various 
physiological and pathological processes mean that the interface at which the interaction 
between receptor and ligand occurs is a promising target for the development of 
molecules to treat human diseases, such as neuron regeneration, bone remodelling 
diseases, and cancer. 
A diverse spectrum of peptides that act as antagonists of Eph-ephrin with 
differential selectivity has previously been identified. One of these peptides, called WDC, 
is attractive because it has been found to antagonize the interaction between EphA5 and 
its ligands with high selectivity. EphA5 receptor and its ligands serve as repulsive 
axonguidance cues in the developing brain. Their interaction triggers growth cone 
collapse and inhibits the neurite outgrowth in vitro. Furthermore, abnormal expression of 
these molecules would result in the disruption of axonal path finding and mid-line 
crossing in vivo. So far, the three-dimensional structure of the EphA5 ligand-binding 
domain has not been determined.  
In the present study, the crystal of EphA5 ligand-binding domain was obtained. 
Structural characterizations of both EphA5 and WDC were assessed by CD and NMR. 
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Furthermore, characterizations of binding interactions between EphA5 and WDC peptide 
were characterized by NMR and ITC.  The binding surface between EphA5 and WDC 
was demonstrated using NMR. 
Interestingly, WDC was found to be well-folded even in the free-state. Its binding 
surface for EphA5 receptor was mapped by Ala site-directed mutagenesis and NMR 
titration. Taken all together, our results may provide critical rationales for further design 
of specific EphA5 antagonists for various therapeutic applications. 
VIII 
 
LIST OF FIGURES  
 
Figure 1    Domain structure and binding interfaces of Eph receptors and ephrins.............2    
Figure 2    Structural comparisons of EphA4 and other Eph ligand-binding domains........5    
Figure 3  Ephrin binding domain of EphB4 receptor in complex with the ephrinB2 
extracellular domain...........................................................................................6 
Figure 4  Ephrin binding domain of EphA2 receptor in complex with the ephrinA1 
extracellular domain...........................................................................................8 
Figure 5    Samples of EphA5 receptor on a 15% SDS-PAGE gel....................................24   
Figure 6   Preliminary structural characterization of EphA5 by CD.................................30 
Figure 7    Crystal structure of the EphA5 ligand-binding domain...................................31 
Figure 8    1H-15N HSQC spectrum of the EphA5 ligand-binding domain........................33 
Figure 9    NMR characterization of the binding between EphA5 and WDC...................34 
Figure 10   ITC characterization of the binding between EphA5 and WDC.....................36 
Figure 11 Comparison of retention time between native and denatured WDC on an 
analytic RP-18 column....................................................................................39 
Figure 12   MALDI-TOF mass spectrum of WDC............................................................40 
Figure 13   Preliminary structural characterization of WDC by CD.................................41 
Figure 14   NMR characterization of WDC.......................................................................43 
Figure 15    Structures of WDC in the ribbon mode as determined by NMR...................45 
Figure 16   Characterization of the binding between 15N-labeled EphA5 and WDC mutant 
peptides as determined by NMR.....................................................................48 
Figure 17   Characterization of the binding between EphA5 and WDC mutant peptides as 
IX 
 
determined by ITC..........................................................................................51  
Figure 18   NMR structures of WDC in the ribbon mode with labelled side chains.........52  
Figure 19   Preliminary structural characterization of WDC and its mutants by CD…....53 
Figure 20    Assigned 1H-15N HSQC spectrum of the EphA5 ligand-binding domain......55 
Figure 21    Assigned 1H-15N HSQC spectrum of the EphA5 ligand-binding domain in the 
presence of 3-fold WDC.................................................................................56 
Figure 22   Secondary structures of EphA5 as calculated by ΔCα and ΔCβ.....................57 





LIST OF TABLES 
 
Table 1   Mutants of WDC peptide and their corresponding oligo nucleotides................21 
Table 2   Thermodynamic parameters of the binding interactions of the EphA5 receptor 
with WDC and its two mutants........................................................................37 
Table 3   Chemical shift of WDC in 10 mM phosphate buffer (pH 6.3) at 15˚C..............44 
XI 
 
 LIST OF ABBREVIATIONS 
 
1D/2D/3D                    One-/Two-/Three-dimensional  
a.a.                                Amino acid  
cDNA                           Complementary DNA  
CD                                Circular Dichroism 
CS                                 Chemical Shift  
Da (kDa)                       Dalton (kilodalton)  
DNA                             Deoxyribonucleic Acid  
DTT                              Dithiothreitol 
E. coli                           Escherichia coli 
EDTA                           Ethylenediaminetetraacetic Acid  
Eph                               Erythropoietin Producing Hepatocellular Receptor 
FID                               Free Induction Decay 
FPLC                            Fast Protein Liquid Chromatography 
g/mg/μg                        Gram/Milligram/Microgram  
GndHCl                        Guanidine Hydrochloride  
GST                              Gluthathione S-transferase 
HSQC                           Heteronuclear Single Quantum Coherence 
IPTG                             Isopropyl-β-D-thiogalactopyranoside 
l/ml/μl                           Liter/Milliter/Microliter 
LB                                 Luria Bertani  
XII 
 
MALDI-TOF MS         Matrix-Assisted Laser Desorption/Ionization Time-of-flight         
Mass Spectroscopy 
min                                Minute 
M (mM)                        Mole/L (Milimole/L)  
MR                                Molecular Replacement 
MW                               Molecular Weight  
NMR                             Nuclear Magnetic Resonance 
NOE                              Nuclear Overhauser Effect 
NOESY                         Nuclear Overhauser Effect Spectroscopy 
OD                                 Optical Density 
PBS                               Phosphate-buffered Saline 
PCR                               Polymerase Chain Reaction 
PDB                               Protein Data Bank 
ppm                               Parts Per Million  
RMSD                           Root Mean Square Deviation 
RP-HPLC                      Reversed-Phase High Performance Liquid Chromatography 
SDS-PAGE                   Sodium Dodecyl Sulfate Polyacrylamide Gel Eletrophoresis 
TOCSY                         Total Correlation Spectroscopy  
Tris                                2-amino-2-hydroxymethyl-1,3-propanediol  
UV                                Ultraviolet  





Figure 1 Sequence alignment of the ligand binding domains of EphA5 with EphA2 and 
EphB2.................................................................................................................71 
Table 1   15N, 15NH and 13C chemical shift of EphA5 at pH 6.3 and 25°C.....................72  
Table 2   15N, 15NH and 13C chemical shift of EphA5 in the presence of 3-fold WDC at 




Chapter I INTRODUCTION 
 
1.1 Introduction to Eph Receptors 
1.1.1  Biological background of Eph receptors 
The erythropoietin-producing hepatocellular carcinoma (Eph) family is the largest 
family of receptor tyrosine kinases identified to date, with 16 structurally similar family 
members (Eph Nomenclature Committee, 1997). Eph is divided into two subclasses, A 
and B, based on binding preferences and sequence conservation. In general, EphA 
receptors (EphA1–EphA10) bind to glycosyl phosphatidyl inositol (GPI)-anchored 
ephrinA ligands (ephrinA1–ephrinA6), whereas EphB receptors (EphB1–EphB6) interact 
with transmembrane ephrinB ligands (ephrinB1–ephrinB3). Although the interactions 
between Eph receptors and eprhins in the same subclass are quite promiscuous, the 
interactions between subclasses are relatively rare (Pasquale, 2008; Gale et al. 1996; Qin 
et al. 2008).  
As shown in Figure 1, Eph receptors have a modular structure that consists of an 
N-terminal ephrin binding domain adjacent to a cysteine-rich domain and two fibronectin 
type III repeats in the extracellular region. The intracellular region consists of a 
juxtamembrane domain, a conserved tyrosine kinase domain, a C-terminal sterile a-
domain, and a PDZ binding motif. The N-terminal 180 amino acid globular domain is 
sufficient for high-affinity ligand binding. The adjacent cysteine-rich region might be 
involved in receptor–receptor oligomerization often observed on ligand binding (Qin et al. 












The communication of biochemical signals between cells is essential for the 
development and existence of multicellular organisms. The direct protein-protein 
interactions between ligands carrying the signal, and cell-surface receptors recognizing 
and transforming the information into the receiving cell are the key method of 
communication (Himanen et al. 2001). Being one of the large groups of receptors and 
ligands, the Eph/ephrin family sends information bidirectionally into both the receptor-
expressing cell and the ligand-expressing cell (Pasquale 2005; Flanagan et al. 1998; 
Himanen et al. 2003; Kullander et al. 2002). Upon ephrin binding, the tyrosine kinase 
domain of the Eph receptors is activated and therefore, initiating ‘forward’ signalling in 
the receptor-expressing cells. At the same time, signals are also induced in the ligand-
expressing cells, a phenomenon referred to as ‘reverse’ signalling (Holland et al. 1996; 
Himanen et al. 2007). 
The Eph/ephrin family plays important roles in both developing and adult tissues, 
and regulates biological processes such as tissue patterning, development of the vascular 
system, axonal guidance, and neuronal development (Pasquale, 2005; Pasquale, 2008; 
Brantley-Sieders et al. 2004). It also has been shown to function in bone remodelling, 
immunity, blood clotting, and stem cells. Recently, the Eph-ephrinB-mediated signalling 
network has been implicated in learning and memory formation, neuronal regeneration, 
pain processing, and differential expressions of ephrinB are also correlated with 
tumorigenesis (Battaglia et al. 2003; Ran et al. 2005).  
 
1.1.2 Structures of Eph receptors and Eph receptor/ephrin complexes 
Because the Eph receptors/ephrins play very important roles in various biological 
4 
 
progresses, the structural study of these Eph/ephrins will help us to understand the 
detailed mechanism of the binding and recognition between Eph receptors and ephrin 
ligands. The structures of the ligand-binding domains of EphA2, EphA4, EphB2 and 
EphB4 have been determined in the Free State and in complex with ephrins or peptide 
antagonists by X-ray crystallography (Qin et al. 2008; Himanen et al. 2001; Himanen et 
al. 2004; Chrencik et al. 2006; Chrencik et al. 2006; Chrencik et al. 2007; Himanen et al. 
2009). These studies have shown that all the Eph ligand-binding domains adopt the same 
jellyroll β-sandwich architecture that are composed of 11 antiparallel β-strands connected 
by loops of various lengths, although they belong to different subclass of Eph receptors 
(Figure 2). Although the H-I loop has no regular secondary structure in all the examined 
EphB receptor structures, the EphA2 and EphA4 receptors form a 310-helix in the H-I 
loop. 
The crystal structures of Eph ligand-binding domains and ephrin indicate that 
initial high affinity binding of Eph receptors to ephrin occurs through the penetration of 
an extended G–H loop of the ligand into a hydrophobic channel on the surface of the 
receptor. In particular, the D-E and J-K loops have been revealed to play a critical role by 
forming the high affinity Eph-ephrin binding channel (Himanen et al. 2009). 
The structure of the EphB2-ephrinB4 complex showed that the ligand-binding 
channel of the receptor is located at the upper convex surface of EphB2, and is formed by 
the flexible J-K, G-H, and D-E loops, which become ordered to accommodate the 
solvent-exposed ephrin G-H loop (Figure 3). A low affinity tetramerization interface, 
which interacts with the C-D loop of the ephrin has also been identified at the concave 





Figure 2: Structural comparisons of EphA4 and other Eph ligand-binding domains. 
(a) Superimposition of the ligand-binding domains of EphA4 Structure A (violet) and 
EphA2 (3C8X; blue). (b) Stereo view of the superimposition of two EphA4 structures 
(structure A in red and structure B in lime green) with previously determined EphB2 and 






















Figure 3: Ephrin binding domain of EphB4 receptor in complex with the ephrinB2 
extracellular domain. EphB4 receptor (red) consists of a jellyroll folding topology with 
13 anti-parallel B-sheets connected by loops of varying lengths, whereas the ephrin 
ligand (blue) is similar to the Greek key folding topology. The interface is formed by 
insertion of the ligand G-H loop into the hydrophobic binding cleft of EphB4. (Chrencik 
et al. 2006) 
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The EphA2/ephrinA1 heterodimer is architecturally similar to the EphB2-
ephrinB4 complexes (Figure 3). The ligand/receptor interface centers around the G–H 
loop of ephrinA1, which is inserted in a channel on the surface of EphA2 (Figures 4). 
Eph receptor strands D, E and J, define the two sides of the channel, whereas strands G 
and M line its back. The ligand binds by approximating the side of its β-sandwich to the 
outside surface of the channel and then inserting its long G–H loop into the channel, 
which finally becomes buttressed by the G–H loop of the receptor closing in from the top. 
The binding is dominated by the Van der Waals contact between two predominantly 
hydrophobic surfaces. Adjacent to the channel/G–H-loop interactions, a second, 
structurally separate, contact area encompasses the ephrinA1 docking site along the upper 
surface of the receptor. Here, the ephrin β-sandwich (strands C, G and F) interacts 
through a network of hydrogen bonds and salt bridges with EphA2 strands D, E and the 
B–C loop region (Himanen et al. 2009). 
Comparison of the EphA2/ephrinA1 structure with the EphB2/ephrinB4 
complexes yields insight into the molecular basis for the observed Eph receptor/ephrin 
subclass specificity (Figures 3, 4). Eph receptor subclass specificity is probably 
maintained in part by the fact that the differences in the structures of the A- and B-class 
molecules result in different architectural arrangements of ligands and receptors in the A- 
and B-subclass complexes. Figures 3 and 4 illustrate that the B-class complexes adopt a 
more ‘compact’ conformation with intimate interactions between the Eph receptor B–C 
region and the juxtaposing C, F and G ephrin strands, whereas the A-class complex is 
more ‘open’ with a smaller number of interactions in the above-mentioned region, but 




Figure 4: Ephrin binding domain of the EphA2 receptor in complex with the 
ephrinA1 extracellular domain EphA2. EphA2 (Blue): residues Glu28–Cys201 and 
ephrin-A1 (Red): residues Ala18–Ile151. (Himanen et al. 2009) 
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and G–H loops of Eph receptor (Himanen et al. 2009). 
The different complex structures suggest that the interactions between receptor 
and ligand in the A-class Eph receptor/ephrin involve smaller rearrangements in the 
interacting partners, better described by a ’lock-and-key’-type binding mechanism, in 
contrast to the ’induced fit’ mechanism defining the B-class molecules (Himanen et al. 
2009). 
 
1.1.3 Drug designs from the structural insights of Eph receptors and ephrin ligands 
As the Eph receptors constitute the largest RTK family, imbalance of Eph/ephrin 
function may therefore contribute to a variety of diseases, such as diabetes, tumor, spinal 
cord injury, abnormal blood clotting and bone remodeling diseases. The critical roles of 
Eph receptors in various physiological and pathological processes have validated the Eph 
receptor as the promising targets for the development of anti-tumor and neuronal 
regeneration drugs (Tang et al. 2007; Fry et al. 2005; Klein 2004; Yamaguchi et al. 2004; 
Goldshmit et al. 2004; Fabes et al. 2006; Fabes et al. 2007).  
According to the structural information for Eph receptors and ephrin ligands, the 
majority of the Eph receptor/ephrin interactions involve the extended G–H ephrin loop 
interacting with the Eph receptor surface channel. It has been proposed that some small 
peptides and chemical compounds could bind to the Eph receptor channel and block Eph 
receptor signaling by preventing ephrin binding to Eph receptor (Qin et al. 2008; Koolpe 
et al. 2002; Chrencik et al. 2006; Chrencik et al. 2007; Koolpe et al. 2002).  
Despite the presence of several binding interfaces, peptides that target the high 
affinity site are sufficient to inhibit Eph receptor-ephrin binding. Interestingly, unlike the 
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ephrins, which bind in a highly promiscuous manner, a number of the peptides that were 
identified by phage display selectively bind to only one or a few of the Eph receptors 
(Koolpe et al. 2005; Chrencik et al. 2007). The antibodies and soluble forms of Eph 
receptors and ephrins extracellular domains that modulate Eph-ephrin interactions have 
also been identified (Pasquale, 2005; Ireton et al. 2005; Noren et al. 2007; Wimmer-
Kleikamp et al. 2005). Several small inhibitors of the Eph receptor kinase domain have 
also been reported. These inhibitors occupy the ATP-binding pocket of the receptors and 
are usually broad specificity inhibitors that target different families of tyrosine kinases 
(Caligiuri et al. 2006; Karaman et al. 2008). 
Recently, two small molecules (2,5-dimethylpyrrolyl benzoic acid derivative and 
its isomeric compound) have been identified by a high throughput screening, which are 
able to antagonize ephrin-induced effects in EphA4-expressing cells. The antagonizing 
benzoic acid derivatives occupy a cavity in the ephrin-binding EphA channel by 
interacting with residues Ile31–Met32 in the D–E loop, Gln43 in the E strand, and Ile131–
Gly132 in the J–K loop (Noberini et al. 2008; Qin et al. 2008). 
 
1.1.4 Functions of EphA5 receptor 
EphA5 receptor is a member of the Eph receptor tyrosine kinase family. It is 
thought to be wildly expressed in most tissues, and higher expression mainly occurs in 
the hippocampus, striatum, hypothalamus, and amygdale in the adult brain (Gerlai et al. 
1999).  
The function of the EphA5 receptor is best characterized as an axon guidance 
molecule during neural development. EphA5 receptor and its ligands act as a repellent 
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cue that prevents axons from entering inappropriate territories, thus restricting the cells to 
specific pathways during the migratory process. During neural development, Eph 
receptors and their ligands are expressed in the projecting and target sites, respectively 
(Wilkinson, 2001; Castellani et al. 1998). 
At the cellular level, the binding of EphA5 receptors with ligands expressing 
neurons results in different consequences depending on the cell type. It has been 
demonstrated that this interaction causes inhibition of the neurite outgrowth of the 
hippocampal, striatal, retinal, and cortical neurons (Brownlee et al. 2000). At the circuit 
level, over expression of a truncated form of EphA5 receptor results in a miswiring of the 
hippocamposeptal pathway and corpus callosum connections in vivo (Yue et al. 2002).  
Taken together, EphA5 receptor and its ligands serve as repulsive axonguidance 
cues in the developing brain. Their interaction triggers growth cone collapse and inhibits 
the neurite outgrowth in vitro. Furthermore, abnormal expression of these molecules 
results in the disruption of axonal path finding and mid-line crossing in vivo (Hu et al. 
2003). 
 
1.2 Structure Determination of Protein/peptide 
Proteins are organic compounds made of amino acids arranged in a linear chain. 
Proteins are an important class of biological macromolecules and present in all living 
organisms. The function of a protein at the molecular level can be better understood by 
determining its three dimensional structure. Common experimental methods of structure 
determination include X-ray crystallography, NMR spectroscopy, and cyro-electron 





1.2.1 Introduction to NMR spectroscopy 
1.2.1.1 NMR  
Nuclear magnetic resonance (NMR) is a property that magnetic nuclei have when 
they are placed in a magnetic field and apply electromagnetic (EM) pulse, which cause 
the nuclei to absorb energy from the EM pulse and then radiate it back out. The NMR 
phenomenon was first detected by Bloch and Purcell independently in 1946 (Bloch, 1946; 
Purcell, 1946), for which they shared the Noble Prize in 1952. NMR spectroscopy was 
first used in the structural determination of small molecules in organic chemistry. The 
application of NMR to protein structure determination only started after Wuthrich 
developed the 2D experiment in the early 1980s (Wuthrich, 1986).  
Nowadays, NMR has become as powerful a technique as X-ray crystallography 
for determining the three dimensional structures of biological macromolecules. So far, 
NMR is the only method for solving protein structure in solution. Furthermore, NMR is 
also available for studying protein dynamics, protein folding and protein/protein 
interaction. With the improved NMR hardware, better developed NMR methodology and 
advanced computer, and multidimensional NMR spectroscopic techniques, today NMR 
has been widely applied in the areas of chemistry, biology and medicine. 
 
1.2.1.2 NMR parameters  
1.2.1.2.1 Chemical shift  
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Chemical shift, which is caused by electric de-shielding effect, is an important 
parameter for identifying individual nucleus and assigning the resonances in the spectrum 
to their corresponding atoms in a molecule. The nuclei within different chemical 
environment will have different resonance frequencies and appear in the spectrum at 
different positions. The reason is that electrons circulating about the direction of the 
applied external magnetic field and the circulation will then cause the generation of a 
small magnetic field at the nucleus. Therefore, each nucleus in an NMR spectrum gives 
rise to a resonance which is characterized by chemical shift that reflects its unique 
chemical environment.  
The characteristic chemical shifts in the amino acids will be helpful for identifying 
individual residues in a protein and determining the protein secondary structure by 
comparing the observed chemical shifts with random coil values (Wishart et al. 1991). In 
order to measure the chemical shift independent of the static magnetic field strength, 
parts per million (ppm) is used to present chemical shift of nucleus.  
 
1.2.1.2.2 J coupling 
J coupling is also referred to as spin-spin coupling or scalar coupling, which is 
mediated through chemical bonds between two spins. Scalar couplings are used in 
multidimensional (2D, 3D, 4D) correlation experiments to transfer magnetization from 
one spin to another in order to identify spin systems. Normally, couplings over one bond, 
two bonds and three bonds are observed (Sattler, 2004). There are two types of J 
couplings: homonuclear and heteronuclear coupling. In homonuclear coupling, the 
coupled nuclei have the same magnetogyric ratio γ, but different chemical shift, such as 
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proton-proton coupling. In heteronuclear coupling, the coupled nuclei have different 














1.2.1.2.3 NOE  
NOE (nuclear Overhauser effect) is a dipolar cross-relaxation phenomenon 
between spins through space magnetization transfer. As a function of interproton 
distances NOE is proportional to the inverse sixth power of the distance (NOE ~ 1/r6) 
between protons at short mixing time. If the interproton distances are larger than 5 Å, the 
NOE probably is too small to be observed.  
NOE provides much information for the 3D structure determination of protein. 
Intra-residue and sequential NOEs not only provide information for establishing 
connections among amino acids, but also reveal protein secondary structure through the 
observed NOE patterns. More importantly, long-range NOE interactions, which can 
correlate protons far apart from protein sequence but close together in space, provide the 
principle source of information for the determination of protein tertiary structure in NMR 
(Wüthrich, 1986).  
 
1.2.2 Introduction to X-ray crystallography 
1.2.2.1 X-ray crystallography 
X-ray crystallography is a method of determining the arrangement of atoms within 
a crystal, in which a beam of X-rays strikes a crystal and diffracts into many specific 
directions. A three-dimensional picture of the density of electrons within the crystal can 
be produced from the angles and intensities of these diffracted beams. And the mean 
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positions of the atoms, their chemical bonds, and disorder in the crystal can then be 
determined by the electron density data. 
X-ray was firstly discovered by the German physicist, Wilhelm Conrad Röntgen 
in 1895. In 1912-1913, William Lawrence Bragg developed Bragg's law, which connects 
the observed scattering with reflections from evenly spaced planes within the crystal. In 
1915, He and his father (William Henry Bragg) shared the Noble Prize in Physics.  
The first crystal structures of protein, sperm whale myoglobin, was solved by Max 
Perutz and Sir John Cowdery Kendrew, for which they were awarded the Nobel Prize in 
Chemistry in 1962 (Kendrew, 1956).  So far, over 48970 X-ray crystal structures of 
proteins, nucleic acids and other biological molecules have been determined. 
Crystallography has a big advantage on solving structures of arbitrarily large molecules, 
whereas solution-state NMR is restricted to relatively small ones (less than 70 kDa).  
 
1.2.2.2 Solution to phase problem 
Direct methods, isomorphous replacement method, anomalous scattering method 
and molecular replacement are the four methods used to solve the phase problem in 
macromolecular structure determination. All these methods only yield phase estimates for 
a limited set of reflections. To improve the accuracy of the phase and to get an 
interpretable electron density map, refinement at both reciprocal and real space is carried 
out with the help of Fourier transformation. 
 
1.2.2.2.1 Direct methods 
The direct method relies on the possible development of useful statistical 
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relationships between sets of structure factors to deduce their phases. However, a crystal 
to be made up of similarly-shaped atoms with positive electron density everywhere must 
be assumed. The direct methods estimate the initial phases for a selected set of reflections 
using a triple relation and extend phases to more reflections. A triple relation is one 
where there are trio of reflections in which the intensity and phase of one reflection can 
be explained by the other two. High resolution data (> 1.2 Å) will be required for the 
direct methods to be successfully applied in protein crystallography (Hauptman H, 1997). 
Therefore, this method is limited to the structure determination of small molecules.  
 
1.2.2.2.2 Multiple isomorphous replacement (MIR)  
Multiple isomorphous replacement is the most common approach of solving the 
phase problem in X-ray crystallography. This method is conducted by soaking the crystal 
of a sample to be analyzed in a heavy atom solution or by co-crystallization the sample 
with the heavy atom. X-ray data sets from the native crystal soaked in a specific heavy 
atom, such as mercury, platinum or gold are collected. For the determination of derivative 
and the positions of the heavy atoms, another data set is then collected by using 
difference Patterson maps. Once the initial heavy atom locations have been determined, 
the coordinates, occupancy and temperature factors of each heavy atom are refined. For 
the structure determination by MIR, at least two isomorphous derivatives must be 
evaluated since using only one will give two possible phases (Taylor, 2003). 
 
1.2.2.2.3 Anomalous scattering 
In X-ray crystallography, anomalous scattering refers to a change in a diffracting 
17 
 
X-ray’s phase that is unique from the rest of the atoms in a crystal due to strong X-ray 
absorbance. Two techniques which are based on anomalous scattering used in X-ray 
crystallography are multi-wavelength anomalous dispersion (MAD) and single-
wavelength anomalous dispersion (SAD). In MAD, the most commonly used atom for 
phase determination is selenium (Ealick, 2000). The selenium is introduced into the 
crystal to replace the natural sulfur containing amino acid methionine by 
selenomethionine, and at least two sets of data are collected at different wavelength. 
However, SAD only uses a single dataset at a single appropriate wavelength. The 
advantage of SAD in contrast to MAD is the minimization of time spent in the beam by 
the crystal, thus reducing potential radiation damage to the molecule while collecting data. 
 
1.2.2.2.4 Molecular replacement (MR) 
The molecular replacement method is used to solve the phase problem when the 
protein molecule has high sequence and structural similarity to an already solved protein 
structure. Firstly, a patterson map, which is considered as a fingerprint of a protein 
structure, is computed from an already solved homologous protein structure. Secondly, 
the patterson map of the homology model is then correctly orientated in the new crystal 
unit-cell by means of rotation functions. Finally, the best fit is achieved by translation 
through the support of a convincing correlation factor and a residual factor. 
 
1.2.2.3 Refinement of initial model 
Because the built initial model is usually not optimal, refinement is needed to 
improve the model. Refinement of a model is the optimization of a function of a set of 
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observations so that the correlation between the atomic model and the diffraction data is 
maximized. Two R factors (R-factor and Rfree-factor) which reflect the quality of the data 
are monitored during the refinement. R-factor (also refers to ‘reliability’) is the agreement 
index between the refined structural models and experimentally observed X-ray 
diffraction data. Rfree-factor is the factor calculated from a subset (~10%) of reflections 
that were not included in the structure refinement. 
 
1.3 Research Aims 
EphA5 receptor plays a very important role in the growth of neuron and many 
signal pathways as mentioned above. However, the three dimensional structure of EphA5 
ligand-binding domain has so far not been determined by NMR or X-ray crystallography. 
Furthermore, Prof. Elena Pasquale and many other scientists have designed some peptide 
inhibitors that inhibit the binding of EphA5 receptor with its ligands.  
 
The research aim of this study has focused on three points. 
(1) To crystallize the EphA5 ligand-binding domain and to resolve its three 
dimensional structure by X-ray crystallography. 
(2) To determine the binding affinity of EphA5 receptor with its antagonistic 
peptides by different biophysical and biochemical methods. 






Chapter II MATERIALS AND METHODS 
 
2.1 Cloning of Proteins and/or Peptides 
The DNA fragment encoding for the human EphA5 ligand-binding domain 
(residues 59–235) was amplified from a HeLa cell cDNA library using two primers 
containing BamHI and XhoI restriction sites, 5’-GGA TCC AAC GAA GTG AAT TTA 
TTG GAT TCA CGC  -3’ (forward) and 5’-CTC GAG TCA AGA AGG CGC TTC TTT 
ATA GTA TAC -3’(reverse). The PCR fragment was cloned into a BamHI and XhoI cut 
pET32a vector (Novagen), and the resulting construct was transformed into Escherichia 
coli Rosetta-gami (DE3) cells (Novagen), allowing more efficient formation of disulfide 
bonds and expression of eukaryotic proteins containing codons rarely used by E. coli. 
The free Cys233 in this construct was mutated to Ala by use of the site-directed 
mutagenesis kit (Stratagene) to avoid the formation of non-native disulfide bridges. 
PCR-based strategy was utilized to synthesize the genes encoding WDC peptide 
(peptide sequence: WDCNGPYCHWLG) (Wei et al. 2005). Briefly, the gene encoding 
WDC was obtained by PCR with two long oligonucleotides: Forward Primer (5’-GGA 
TCC TGG GAT TGC AAC GGC CCG TAT TGC CAT TG -3’) and Reverse Primer (5’-
CTC GAG TCA GCC CAG CCA ATG GCA ATA CGG GCC-3’) with a 17-mer overlap 
designed with E. coli preferred codons containing BamHI and XhoI restriction sites. The 
PCR fragment was cloned into a BamHI and XhoI cut pGEX-4T-1 vector (Amersham 
Biosciences), and the vector was transformed into E. coli Rosetta-gami (DE3) cells 





2.2 Selection of Residues for Sit-directed Mutagenesis 
In order to identify the residues in WDC that bind with EphA5, an alanine site-
directed mutagenesis screen of WDC was conducted. PCR-based strategy was also 
utilized to synthesize the genes encoding WDC-mutant peptides as described above. The 
mutated peptide sequences and the DNA oligo nucleotides are listed in Table 1.  The 
PCR fragment was cloned into a BamHI and XhoI cut pGEX-4T-1 vector (Amersham 
Biosciences), and the resulting construct was transformed into E. coli Rosetta-gami (DE3) 
cells (Novagen), as described above. All DNA constructs were confirmed by automated 
sequencing prior to expression of the recombinant proteins. 
 
2.3 Transformation of E. coli Cells 
Two microliters of plasmid DNA was transferred to the tube containing 50 µL of 
E. coli competent cells and gently mixed. The cells were then cooled on ice for 30 min, 
followed by a heat shock at 42°C for 90 seconds and then cooled on ice for 2 min. LB 
medium (500 µL) was added to the tube and incubated for 1 hr at 37°C with shaking at 
100 rpm. After incubation, the cells were plated onto LB Agar plates containing 100 
µg/ml ampicillin. 
 
2.4 Expression and Purification of EphA5 and Peptides 




Table 1: Mutants of WDC peptide and their corresponding oligo nucleotides 
 
Name Amino Acid sequence Primers 
1WA ADCNGPYCHWLG 
Forward 5’-GGA TCC GCG GAT TGC AAC GGC CCG TAT TGC CAT TG-3’ 
Reverse 5’-CTC GAG TCA GCC CAG CCA ATG GCA ATA CGG GCC-3’ 
2DA WACNGPYCHWLG 
Forward 5’-GGA TCC TGG GCG TGC AAC GGC CCG TAT TGC CAT TG-3’ 
Reverse 5’-CTC GAG TCA GCC CAG CCA ATG GCA ATA CGG GCC-3’ 
4NA WDCAGPYCHWLG 
Forward 5’-GGA TCC TGG GAT TGC GCG GGC CCG TAT TGC CAT TG-3’ 
Reverse 5’-CTC GAG TCA GCC CAG CCA ATG GCA ATA CGG GCC-3’ 
6PA WDCNGAYCHWLG 
Forward 5’-GGA TCC TGG GAT TGC AAC GGC GCG TAT TGC CAT TG-3’ 
Reverse 5’-CTC GAG TCA GCC CAG CCA ATG GCA ATA CGC GCC-3’ 
7YA WDCNGPACHWLG 
Forward 5’-GGA TCC TGG GAT TGC AAC GGC CCG GCG TGC CAT TG-3’ 
Reverse 5’-CTC GAG TCA GCC CAG CCA ATG GCA CGC CGG GCC-3’ 
9HA WDCNGPYCAWLG 
Forward 5’-GGA TCC TGG GAT TGC AAC GGC CCG TAT TGC GCGTG-3’ 
Reverse 5’-CTC GAG TCA GCC CAG CCA CGC GCA ATA CGG GCC-3’ 
10WA WDCNGPYCHALG 
Forward 5’-GGA TCC TGG GAT TGC AAC GGC CCG TAT TGC CAT GC-3’ 
Reverse 5’-CTC GAG TCA GCC CAG CGC ATG GCA ATA CGG GCC-3’ 
11LA WDCNGPYCHWAG 
Forward 5’-GGA TCC TGG GAT TGC AAC GGC CCG TAT TGC CAT TG-3’ 
Reverse 5’-CTC GAG TCA GCC CGC CCA ATG GCA ATA CGG GCC-3’ 
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The recombinant EphA5 was over expressed in E. coli Rosetta-gami (DE3) cells. 
Briefly, the cells were cultured in Luria-Bertani medium at 37°C until the absorbance at 
600 nm reached ~0.6. Isopropyl 1-thio-D-galactopyranoside (IPTG) was then added to a 
final concentration of 0.1 mM to induce EphA5 expression at 18°C for overnight. The 
harvested cells were sonicated in the lysis buffer containing 20 mM sodium phosphate 
(pH 7.3) and 150 mM sodium chloride to release soluble His-tagged proteins, which were 
subsequently purified by affinity chromatography using nickel-nitrilotriacetic acid-
agarose (Qiagen). In-gel cleavage of the EphA5 fusion protein was performed at room 
temperature by incubating the fusion protein attached to nickel-nitrilotriacetic acid-
agarose with thrombin overnight. The released EphA5 protein was further purified on an 
AKTA FPLC machine (Amersham Biosciences) using a gel filtration column (HiLoad 
16/60 Superdex 200) equilibrated in 20 mM sodium phosphate (pH 7.3) containing 150 
mM sodium chloride. 
For the crystallization of EphA5, the harvested cells were sonicated and protein 
was purified by gel filtration in 25mM Tris-HCl (pH 7.8), containing 150mM NaCl and 
5mM CaCl2. To increase the purity of the EphA5, the eluted fractions from gel filtration 
step were combined and buffer exchanged to 25mM Tris-HCl (pH 7.8), and then purified 
by ion-exchange chromatography using anion-exchange column (Mono Q 5/50). The 
column was eluted with a gradient of NaCl from 0 to 1 M in 25 mM Tris-HCl (pH 7.8). 
The eluted fraction containing the EphA5 ligand-binding domain was collected and again 
buffer exchanged to 25 mM Tris-HCl (pH 7.8), containing 150 mM NaCl and 5 mM 
CaCl2 for storage. The purity of the protein was verified by the SDS-PAGE, and the 
identity of EphA5 was verified by MALDI-TOF mass spectrometry. 
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2.4.2   Expression and purification of WDC and its mutants 
The recombinant WDC and its mutants were overexpressed in E. coli Rosetta-
gami (DE3) cells. Briefly, the cells were cultured in Luria-Bertani medium at 37°C until 
the absorbance at 600 nm reached ~0.6. Isopropyl 1-thio-D-galactopyranoside was then 
added to a final concentration of 0.5 mM to induce peptides expression at 20°C overnight. 
The harvested cells were sonicated in lysis buffer containing 20 mM sodium phosphate 
(pH 7.3) and 150 mM sodium chloride to release soluble GST-tagged peptides, which 
were subsequently purified with glutathione-Sepharose (Amersham Biosciences). The 
peptides were released from the GST fusion proteins by in-gel thrombin cleavage 
followed by HPLC purifications on a RP-18 column (Vydac). The formation of disulfide 
bridge of WDC and its mutants was determined by both HPLC and MALDI-TOF mass 
spectrometry. 
  
2.4.3 Preparation of the isotope-labelled protein and/or peptides 
The generation of the isotope-labelled protein and peptides for NMR studies 
followed a similar procedure except that the bacteria were grown in M9 medium with the 
addition of (15NH4)2SO4 for 15N labelling and (15NH4)2SO4/[13C]glucose for 15N-/13C 
double labelling. The concentration of protein and peptides samples was determined by a 
spectroscopic method (Beer-Lamber Law) in the presence of 6 M guanidine 
hydrochloride (Pace et al. 1995). 
 
2.5 Circular Dichroism (CD) Measurement  
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The CD spectra of peptides and proteins were recorded in 10 mM phosphate 
buffer (pH 6.3) on a Jasco J-810 spectropolarimeter equipped with a thermal controller 
(Liu et al. 2006). The samples at a protein concentration of ~20 µM were scanned in a 
capped quartz cuvette of 1-mm path length in the wavelength range of 260-190 nm at 
25°C under nitrogen flush. Data from three independent scans were added and averaged. 
 
2.6  Crystallization of EphA5   
The EphA5 ligand-binding domain was prepared at a concentration of 10 mg/ml in 
a buffer containing 25 mM Tris-HCl (pH 7.8), 150 mM NaCl and 5 mM CaCl2. Crystal 
screen was set up by preparing 2-µl hanging drops at room temperature in a well 
containing different reservoir solution. Rock-like crystals formed in the well containing 
0.1 M Tris-HCl (pH 8.5) and 2.0 M ammonium sulfate. After careful optimization of the 
concentration of ammonium sulfate and the pH of Tris-HCl, high quality crystals grew 
after 3 days under the condition of 0.1 M Tris-HCl (pH 8.5) and 2.0 M ammonium sulfate. 
 
2.7 Characterization of the Binding of EphA5 with WDC and its Mutants by HSQC 
of NMR 
To characterize the binding interaction of WDC and its mutants with EphA5 by 
NMR, two-dimensional 1H-15N HSQC spectra of the 15N-labeled EphA5 were acquired at 
a protein concentration of ∼100 μM in the absence or presence of WDC and its mutants 
at different molar ratios. By superimposing the HSQC spectra of the 15N-labeled EphA5 
in the absence and presence of peptides, the shifted HSQC peaks could be identified. 
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Similarly, the binding interaction between WDC and EphA5 was further 
investigated by monitoring the shifts of HSQC peaks in the spectra of the ∼100 μM 15N-
labeled WDC peptide upon addition of unlabeled EphA5. 
 
2.8 Characterization of the Binding of EphA5 with WDC and its Mutants by 
Isothermal Titration Calorimetry (ITC) 
All ITC experiments were performed using a Microcal VP ITC machine. 
Titrations of the binding of WDC and its mutants to EphA5 were conducted in 10 mM 
phosphate buffer (pH 6.3) and at 25°C. The EphA5 was placed in a 1.8-mL sample cell, 
while the peptides were loaded into a 300 μL syringe. The samples were degassed for 15 
min and spun down for 5 min to remove bubbles before titrations were initiated. A 
control experiment with the same parameter setting was also performed to subtract the 
contribution of the peptide dilution. The titration data after the results of the control 
experiment had been subtracted were fitted using the built-in software ORIGIN to yield 
the thermodynamic binding parameters. 
 
2.9 NMR Experiments of EphA5 and WDC 
2.9.1 Backbone assignment of EphA5 
Double-labeled EphA5 (0.5 mM) with or without WDC was prepared in 10 mM 
phosphate buffer (pH 6.3) with the addition of 10% D2O for NMR spin-lock. For the 
preliminary backbone sequential assignment, a pair of triple-resonance NMR spectra, 
HNCACB and CBCA(CO)NH were collected at 25°C on an 800-MHz Bruker Avance 
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spectrometer equipped with a shielded cryoprobe. All NMR data were processed with 
NMRPipe and analyzed with NMRView. 
 
2.9.2 Structure determination of WDC by NMR 
A 1.0 mM solution of WDC was prepared in 10 mM phosphate buffer (pH 6.3) 
with the addition of 10% D2O for the 2D 1H TOCSY and NOESY experiments. The 
NMR spectra were collected at 15°C on an 800-MHz Bruker Avance spectrometer 
equipped with a shielded cryoprobe. All NMR data were processed with NMRPipe and 
analyzed with NMRView.  
For structure calculation, a set of manually assigned unambiguous NOE restraints 
extracted from two-dimensional 1H NOESY spectra were input to calculate initial 
structures with CYANA. With the availability of the initial structure, more NOE 
crosspeaks in the two NOESY spectra were automatically assigned by CYANA program 
followed by extensive manual confirmation and correction. After several rounds of 
refinement, the final set of unambiguous NOE, and disulfide bridge were input for the 
structure determination by CYANA. The 10 lowest-energy structures accepted by the 





Chaper III EXPERIMENTAL RESULTS AND DISCUSSIONS 
 
3.1 Expression and purification of EphA5 Ligand-Binding Domain 
The recombinant EphA5 was over expressed in E. coli Rosetta-gami (DE3) cells 
to increase the correct formation of disulfide bridge. The released soluble recombinant 
His-tagged EphA5 proteins were purified by affinity chromatography using nickel-
nitrilotriacetic acid-agarose (Qiagen). After in-gel cleavage of the EphA5 fusion protein 
with thrombin overnight at room temperature, the released EphA5 protein was further 
purified on an AKTA FPLC machine. The expression of EphA5 and the purity of the 
purified protein were assessed by SDS-PAGE using 15% gel (Figure 5). Since His-tag 
has a molecular weight of around 2 kDa, EphA5 without the His-tag migrated faster 
compared to His-tagged-EphA5 from the beads.   
For crystallization, the purity of purified EphA5 was further enhanced by ion-
exchange chromatography using an anion-exchange column (Mono Q 5/50). The protein 
eluted from the Mono Q5/50 column appeared homogenous as determined by SDS-
PAGE (data not shown).  
 
3.2 Structural Characterization of EphA5 by CD  
After the EphA5 ligand-binding domain was successfully purified by FPLC, its 
structural property was first assessed by far-UV CD spectroscopy. As shown in Figure 
6A, the spectrum of the protein showed a maximal negative signal at ∼213 nm. This 
implied that EphA5 is a typical β-protein (Figure 6A). To see the overall tertiary packing 




Figure 5: Samples of EphA5 receptor on a 15% SDS-PAGE gel. Lane 1, Total cell 
extract before induction. Lane 2, Total cell extract with a 0.1 mM isopropyl-1-thio-b-D-
galactopyranoside induction at 20˚ C for overnight; Lane 3, Supernatant of the cell lysate 
solubilised in the PBS buffer (pH 7.3); Lane 4, Pellet of the cell; Lane 5, Flow-through 
fraction after passing through Ni2+-affinity column; Lane 6, Flow-through fraction from 
extensive washing with PBS buffer (pH 7.3); Lane 7, Ni2+-agarose beads after an 
extensive PBS buffer-washing; Lane 8: Elution of EphA5 receptor after overnight in-gel 




guanidinium chloride were recorded (Figure 6B). The near-UV CD spectra showed that 
without the denaturant guanidinium chloride, EphA5 adopted tight tertiary packing, a 
property that was lost under denaturation condition. 
Moreover, thermal unfolding study for EphA5 was conducted and the result 
indicated the existence of a relatively cooperative unfolding transition from 55 to 75⁰C 
(Figure 6C, D). However, EphA5 still had a far-CD spectrum with a maximal negative 
signal at ∼215 nm at 95⁰C, which implied that thermal unfolding was insufficient to 
completely denature EphA5 even at a temperature as high as 95⁰C. 
 
3.3 Crystal Structure of EphA5 Ligand-Binding Domain 
The EphA5 ligand-binding domain purified by anion-exchange chromatography 
was crystallized under the condition of 0.1 M Tris-HCl (pH 8.5) and 2.0 M ammonium 
sulfate. The crystal structure of EphA5 ligand-binding domain was determined by the 
Molecular Replacement method using EphA4 ligand-binding domain as a search model. 
The crystal structure was refined at 2.6 Å resolution with a final R-factor of 0.2049 
(Rfree=0.2824). The atomic coordinates were deposited in the Protein Data Bank with the 
PDB ID of 3DLY. The EphA5 ligand-binding domain exhibited both the conserved 
jellyroll folding architecture and a compact β-sandwich (Figure 7). The jellyroll consists 
of 11 anti-parallel β-sheets connected by loops of varying length and two disulfide bonds. 
 
3.4 Structural Characterization of EphA5 by NMR  


















































































































































Figure 6: Preliminary structural characterization of EphA5 by CD. (A) Far-UV CD 
spectrum of 20 µM EphA5 in the 10 mM phosphate buffer (pH 6.3). (B) Near-UV CD 
spectra of 20 µM EphA5 in 10 mM phosphate buffer (pH 6.3) without (black line) and 
with 6 M guanidinium chloride (dash line). (C) Far-UV CD spectra of EphA5 during the 







Figure 7: Crystal structure of the EphA5 ligand-binding domain.  
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solution, HSQC spectrum of EphA5 was obtained (Figure 8). EphA5 had a well- 
dispersed HSQC spectrum with 4.1ppm for 1H dimension and 28.1ppm for 15N dimension, 
respectively. This result indicated that EphA5 protein had a well-packed tertiary structure 
as confirmed by the data from CD spectra. Therefore, NMR would be suitable for 
studying the structure of EphA5 and binding affinity of EphA5 for ligands. 
 
3.5 Characterization of Binding Interactions between EphA5 and WDC Peptide by 
NMR 
The NMR titration was used to determine the binding affinity between EphA5 and 
WDC peptide.  Two-dimensional 1H-15N HSQC spectrum of ∼100 μM 15N-labeled 
EphA5 in10 mM phosphate buffer (pH 6.3) at 25 °C was first recorded with an 800 MHz 
Bruker NMR spectrometer. After successive addition of WDC, the 1H-15N HSQC spectra 
of 15N-labeled EphA5 were then recorded again in the same parameters.  
At a molar ratio of 1:1, two sets of the HSQC peaks were observed for almost all 
residues of the EphA5 ligand-binding domain. One set which represented the free EphA5 
had no peak shift, whereas the other set which represented the EphA5-WDC peptide 
complexes showed extensive peak shifts. When the molar ratio of EphA5 to WDC 
reached 1:3, the HSQC peak set from the free 15N-labeled EphA5 all shifted to become 
identical with the set from the complexes of EphA5 and WDC (Figure 9A). After further 
addition of WDC to a molar ratio of 1:4, the HSQC peaks did not exhibit significant 
















Figure 9: NMR characterization of the binding between EphA5 and WDC. (A) 
Superimposition of the HSQC spectra of the 15N-labeled EphA5 in the absence (blue) and 
presence (red) of WDC at a molar ratio of 1:3. (B) Superimposition of the HSQC spectra 
of the 15N-labeled WDC in the absence (blue) and presence (red) of EphA5 at a molar 
ratio of 1:3. Both spectra were acquired in 10 mM phosphate buffer (pH 6.3) at 25 °C 
using an 800 MHz Bruker NMR spectrometer. (C) Superimposition of the HSQC spectra 
of the 15N-labeled WDC in the absence (blue) and presence (red) of EphA5 at a molar 
ratio of 1:3. Spectra were acquired in 10 mM phosphate buffer (pH 6.3) at 15°C using an 
800 MHz Bruker NMR spectrometer.  
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Meanwhile, the binding interaction between EphA5 and WDC was further 
investigated by monitoring the shifts of HSQC peaks of the ∼100 μM 15N-labeled WDC 
peptide upon successive additions of unlabeled EphA5. Similarly, at a WDC to EphA5 
molar ratio of 1:3, the HSQC peak set from the free 15N-labeled WDC all shifted to 
become identical with the set from the complexes of EphA5 and WDC at both 25°C and 
15°C (Figure 9B and C). 
 
3.6 Characterization of Binding Interactions between EphA5 and WDC Peptide by 
ITC  
To analyze the binding affinity of the EphA5 ligand-binding domain for WDC, 
ITC was utilized to measure their thermodynamic binding parameters. Figure 10 
presented the ITC profile for the interaction of EphA5 with WDC at 25°C. After the 
profile was fitted by ORIGIN software, the thermodynamic parameters were obtained as 
shown in Table 2. The Kd for the binding of EphA5 with WDC was 6.22 µM, which 





Figure 10: ITC characterization of the binding between EphA5 and WDC. (A) ITC 
titration profiles of the binding reaction between EphA5 and WDC. (B) Integrated values 
for reaction heat with subtraction of the corresponding blank results normalized by the 
amount of ligand injected versus WDC/EphA5 molar ratio. The detailed conditions and 





Table 2: Thermodynamic parameters of the binding interactions between EphA5 
receptor with WDC and its two mutants 
Syringe Cell Temp (⁰C) 
Injection 
Volume (µL) Ka (M
-1) Kd (µM) ΔS ΔH 
WDC        
(500 µM) 
EphA5 
(28 µM) 25 5 1.608×10
5±1.412×104 6.22 -0.04263 -7118±138.6 
1WA         
(500 µM) 
EphA5 
(28 µM) 25 5 2.595×10
5±1.557×104 3.85 -1.653 -7750±89.05 
4NA          
(500 µM) 
EphA5 
(25 µM) 25 5 0.891×10
5±0.522×104 11.22 -1.201 -6995±122.5 




3.7 Structural Characterization of WDC by CD 
HPLC-purified WDC peptide was dried by lyophilization for two days. The 
formation of disulfide bridge in WDC was confirmed by HPLC (Figure 11) and by 
MALDI-TOF mass spectrometry (Figure 12).  
As shown in the Figure 11, native WDC showed one peak in the HPLC profile, 
whereas WDC denatured by 8 M urea and 100 mM DTT showed two peaks. The first 
peak possessed the same retention time as native WDC, and the second peak had a ~1 
min delayed retention time, which implied the disulfide bridge of WDC had been 
disrupted by 100 mM DTT. Mass spectroscopy analysis of WDC yielded a molecular 
weight of 1592.5 Da, which was consistent with its calculated value of 1592.7 Da (Figure 
12). 
The structural property of WDC was first investigated by far-UV CD spectroscopy 
in 10 mM phosphate buffer (pH 6.3) at 25°C.  As shown in Figure 13A, the far-UV 
spectrum of WDC has a maximal negative signal at ∼212 nm, which indicated the 
presence of β strand structure, formed as a result of the presence of disulfide bridge 
between Cys5 and Cys10.  
Moreover, the result from thermal unfolding study of WDC showed that the CD 
spectra of WDC shifted to a maximal negative peak at ~201nm at a temperature of 75°C 
or higher, which implied that WDC had become unstructured (Figure 13 B and C).  
 
3.8 Structural Characterization of WDC by NMR 
To explore the structural properties of WDC, NMR spectroscopy was further 





Figure 11: Comparison of retention time between native and denatured WDC on an 
analytic RP-18 column.  Blue line: WDC in 10 mM phosphate buffer (pH 6.3); Black 
line: WDC denatured in 8 M urea and 100 mM DTT plus 10 mM phosphate buffer (pH 




Figure 12: MALDI-TOF mass spectrum of WDC. Peptide was desalted and re-
dissolved in water. The calculated MW of WDC was 1592.7 Da and the determined MW 
of WDC was 1592.5 Da. 
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Figure 13: Preliminary structural characterization of WDC by CD. (A) Far-UV CD 
spectrum of 50 µM WDC in the 10 mM phosphate buffer (pH 6.3). (B) Far-UV CD 
spectra of WDC collected at a 10˚C interval during the thermal unfolding from 5 to 95˚C. 
(C) The thermal unfolding curve monitored at 216 nm. 
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peaks from all amino acid except Gly1 were visible. Therefore, it was possible to assign 
all amino acids of WDC.   
To obtain better spectra, both TOCSY and NOESY spectra were acquired not at 
25°C but at 15°C in 10 mM phosphate buffer (pH 6.3). The mixing time in NOESY 
spectrum was 75 ms (Figure 14B).  
As the binding of WDC by EphA5 was saturated at a WDC to EphA5 molar ratio 
of 1:3 at both 25°C and 15°C, the binding between WDC and EphA5 appeared not to be 
significantly affected by temperature (Figures 9B and C). Furthermore, WDC had similar 
CD spectra in both 25°C and 15°C, which showed that temperature had no significant 
effect on its structure.  
 
3.9 NMR Structure of WDC 
2D 1H TOCSY and NOESY experiments of 1mM WDC in 10 mM phosphate 
buffer (pH 6.3) were first collected at 15°C on an 800-MHz Bruker Avance spectrometer 
equipped with a shielded cryoprobe. All NMR data were then processed with NMRPipe 
and analyzed with NMRView. 
According to TOCSY and NOESY spectra, the preliminary sequential assignment 
was completed. The assigned 1H chemical shifts of WDC were presented in Table 3. The 
NMR structure of WDC was further calculated from the NOE restraints by CAYNA 
program, and 10 lowest-energy accepted structures were selected after several rounds of 
refinement. The 10 selected NMR structures of WDC in solution are showed in Figure 15. 




       
Figure 14: NMR characterization of WDC. (A) HSQC spectrum of the 15N-labeled 
WDC acquired in 10 mM phosphate buffer (pH 6.3) at 15°C on an 800 MHz Bruker 
NMR spectrometer. (B) NH-aliphatic region spectra of TOCSY (red) and NOESY (blue) 
acquired in 10 mM phosphate buffer (pH 6.3) at 15°C on an 800 MHz Bruker NMR 
spectrometer (Mixing time for NOESY is 75 ms). 
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Table 3: Chemical shift of WDC in 10 mM phosphate buffer (pH 6.3) at 15˚C 
NO Residue NH Hα Hβ Hγ Hδ other 
1 Gly       
2 Ser 7.774 4.138 3.488    3.519 
3 Trp 8.361 4.656 2.872   7.162, 10.048 6.462, 6.820 3.033 
4 Asp 8.669 4.633 2.274    2.386 
5 Cys 8.554 4.843 2.801    2.935 
6 Asn 8.48 4.65 2.653   6.808 2.687 7.589 
7 Gly 8.429 3.666     4.047 
8 Pro  4.136 1.693 1.317 3.368  1.928 1.467 3.534 
9 Tyr 7.34 4.558 2.776   6.61 2.962 6.92 
10 Cys 8.302 5.013 2.411    2.716 
11 His 8.675 4.795 3.05   7.019 3.093 8.22 





6.931, 6.606 2.788 
13 Leu 8.279 4.125 1.181  0.588  1.272 0.631 











Figure 15: Structures of WDC in the ribbon mode as determined by NMR.
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 revealed root mean squared deviations (RMSD ) of  0.33 ± 0.15 Å for the backbone 
atoms (N, Cα, C’, O) and 0.53 ± 0.07 Å for all heavy atoms from mean structures. 
WDC has a single disulfide bridge (Cys5-Cys10) forming a 4-residue ring, in which 
the presence of Gly6 and Pro7 assists with the formation of a β-turn, since Gly and Pro are 
generally believed to be present at the β-turn (Figure 15).  
In order to determine the structure of WDC in the presence of EphA5, 3D HSQC-
TOCSY and NOESY experiments were performed with 1mM 15N-WDC in 10 mM 
phosphate buffer (pH 6.3) in the presence of EphA5 at a WDC to EphA5 molar ratio of 
1:3. Spectra were collected at 15°C on an 800-MHz Bruker Avance spectrometer 
equipped with a shielded cryoprobe. Unfortunately, it was not possible to finish the 
sequential assignment after the NMR data were processed, because many 1H signal of 
WDC in the complex with EphA5 were not visible (data not shown). 
 
3.10 Mapping of Binding Interface between EphA5 and WDC by NMR 
All the above data showed that WDC can bind with EphA5 receptor with medium 
affinity. It was of interest to study the surface the EphA5 ligand-binding domain and 
WDC where binding actually occurs. As attempts to co-crystallize EphA5 with WDC 
were not successful, NMR spectroscopy was used to map the binding interface between 
EphA5 receptor and WDC peptide.  
 
3.10.1 Mapping of EphA5-binding interface within WDC by NMR and ITC 
3.10.1.1 Interaction of WDC-mutant peptides with EphA5 by NMR 
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       To map the residues within WDC that are involved in the binding of EphA5, the 
binding interactions between EphA5 and eight WDC-mutant peptides were studied by 
HSQC titrations (Figure 16). All amino acids in WDC, except for glycine and cysteine, 
were mutated by an alanine site-directed mutagenesis screen. The peptides sequences of 
all these mutants are shown in Table 1. 
Two dimensional 1H-15N HSQC spectra of the 15N-labeled EphA5 receptor were 
acquired in the absence and presence of peptides at different EphA5 to peptide molar 
ratios. For 1WA (Figure 16A) and 4NA (Figure 16C) peptides, their binding interaction 
with EphA5 were the same as that between EphA5 and WDC. At a molar ratio of 1:1, 
two sets of the HSQC peaks were observed for almost all the residues of the EphA5 
ligand-binding domain. When the molar ratio of EphA5/peptide reached 1:3, the HSQC 
peak set from the free 15N-labeled EphA5 all shifted to merge with the set from the 
complexes of EphA5 and WDC. At a molar ratio of 1:4, the binding of EphA5 to these 
two WDC-mutant peptides was saturated. These results showed that replacement of Trp3 
and Asn6 with Ala did not significantly affect the binding between WDC and EphA5, and 
implied that Trp3 and Asn6 in WDC may not be involved in the binding surface for 
EphA5 receptor. 
However, no detectable perturbation of the HSQC peak was observed even at an 
EphA5 to peptide molar ratio of 1:10 for 2DA (Figure 17B), 6PA (Figure 17D), 7YA 
(Figure 16E), 9HA (Figure 16F), 10WA (Figure 16G) and 11LA (Figure 16H) peptides. 
These results implied that Asp4, Pro8, Tyr9, His11, Trp12, and Leu13 could play a very 
important role for the binding of WDC to EphA5 receptor. Therefore, no further ITC 










Figure 16: Characterization of the binding between 15N-labeled EphA5 and WDC 
mutant peptides as determined by NMR. Superimposition of HSQC spectra for the 
15N-labeled EphA5 in the absence (blue) and presence (red) of WDC mutant peptides at a 
different molar ratios. All spectra were acquired in 10 mM phosphate buffer (pH 6.3) 
except 2DA (pH 5.6) at 25°C on an 800 MHz Bruker NMR spectrometer. (A) 1WA; (B) 
2DA; (C) 4NA; (D) 6PA; (E) 7YA; (F) 9HA; (G) 10WA; (H) 11LA. 
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3.10.1.2 Interaction of WDC-mutant peptides with EphA5 by ITC 
The thermodynamic binding parameters of the EphA5 ligand-binding domain with 
1WA and 4NA were analyzed by ITC at 25°C. As shown in Figure 17 and Table 2, Kd for 
the binding between EphA5 and 1WA and between EphA5 and 4NA were 3.85 µM and 
11.22 µM, respectively, which is consistent with the Kd for the binding of EphA5 with 
WDC. Again, it demonstrated that Trp3 and Asn6 in WDC may not be involved in the 
binding WDC to EphA5 receptor. 
Taken together, Asp4, Pro8, Tyr9, His11, Trp12, and Leu13 in WDC could play a 
very important role in its binding to EphA5 receptor. To clearly show these binding sites, 
all side chains of Asp4, Pro8, Try9, His11, Trp12 and Leu13 are shown in red colour in a 
stick mode in Figure 18. 
 
3.10.1.3 Structural comparison of WDC and its mutant peptides by CD  
To gain insight into the globular secondary structural changes in WDC caused by 
the Ala site-directed mutagenesis, far-UV CD spectra of all eight WDC-mutant peptides 
and native WDC were collected. All CD spectra were collected at pH 6.3 and 25°C in 10 
mM phosphate buffer except for 2DA, whose CD spectrum was collected at pH 5.6.  
It was interesting to notice that except for 1WA and 10WA, in which one of the 
Trp was replaced by Ala, all six WDC-mutant peptides had same CD spectrum as WDC 
(Figure 19). Comparison of the spectra of 1WA and 10WA against the spectrum of native 
WDC indicated that a positive peak around 225 nm disappeared in the spectra of both 





Figure 17: Characterization of the binding between EphA5 and WDC mutant 
peptides as determined by ITC. ITC titration profiles of the binding reactions of the 
1WA (A) and 4NA (C) with EphA5. Integrated values for reaction heats with subtraction 
of the corresponding blank results normalized by the amount of ligand injected versus 
1WA:EphA5 (B) and 4NA:EphA5 (D) molar ratio. The detailed conditions and settings 





Figure 18: NMR Structures of WDC in the ribbon mode with labelled side chains. 
The side chains of Asp4, Pro8, Try9, His11, Trp12 and Leu13 were displayed in stick mode 




































Wavelength (nm)  
Figure 19: Preliminary structural characterization of WDC and its mutants by CD. 
Far-UV CD spectra of 50 µM peptides in the 10 mM phosphate buffer (pH 6.3), except 
2DA (pH 5.6). 
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Ala had significantly affected the secondary structure of peptides as the negative band 
around 225 nm could be caused either by the tryptophan side chains or turn structures 
(Nagpal et al. 1999). 
Further study of the effect of mutation on the structure of WDC would require the 
acquisition of 2D 1H TOCSY and NOESY NMR spectra for these mutant peptides.  
 
3.10.2 Mapping of EphA5-binding interface to WDC by NMR  
3.10.2.1 Backbone sequential assignment of EphA5 without and with WDC 
15N/13C double-labelled EphA5 of 0.5 mM concentration were prepared in 10 mM 
phosphate buffer (pH 6.3). A pair of triple-resonance NMR spectra, HNCACB and 
CBCA(CO)NH was collected at 25°C to obtain the preliminary backbone sequential 
assignment for EphA5 in the absence and presence of WDC (a WDC to EphA5 molar 
ratio of 1:3), respectively. The 1H-15N HSQC spectra of assigned EphA5 backbone peaks 
in the absence and presence of WDC are shown in Figure 20 and Figure 21, respectively.  
To evaluate whether the sequential assignment was correct, both Cα and Cβ 
conformational shifts were calculated. Figure 22 shows that the conformation of β-strands 
in EphA5 was consistent with the determined conformation obtained by X-ray 
crystallography. Furthermore, the completed NMR sequential assignments for the EphA5 
ligand-binding domain in the absence and presence of WDC indicated that binding of 











Figure 21: Assigned 1H-15N HSQC spectrum of the EphA5 ligand-binding domain in 






Figure 22: Secondary structures of EphA5 as calculated by ΔCα and ΔCβ. (A) Cα 
conformational shifts of EphA5 to Random Cα (ΔCα) in the presence (blue) and absence 
(red) of WDC. (B) Cβ conformational shifts of EphA5 to Random Cβ (ΔCβ) in the 






3.10.2.2 Mapping of EphA5-binding interface to WDC by chemical shift 
perturbation analysis 
Because the chemical shift value of an NMR active atom is sensitive to its 
chemical environment, chemical shift perturbation analysis upon titration of ligands 
represents a powerful method for identifying residues that directly contact the ligands or 
that are indirectly affected by the binding event (Qin et al. 2008). 
As shown in Figure 9, the HSQC peak set from the free 15N-labeled EphA5 all 
shifted to become identical with the set from the complexes of EphA5 and WDC when 
the molar ratio of EphA5 to WDC reached 1:3. After further addition of WDC to a molar 
ratio of 1:4, the HSQC peaks did not exhibit significant further shift, indicating that the 
binding of EphA5 by WDC had become saturated. Therefore, to identify the interaction 
surfaces of EphA5 to WDC, the chemical shift differences (CSD) between the free state 
and the complex state (EphA5/WDC molar ratio of 1:3) were calculated according to the 
formula ((Δ1H)2 + (Δ15N)2 /5)1/2, and the results were plotted against EphA5 sequence as 
shown in Figure 23. 
There were twelve resonance peaks with significant CSD (residues of EphA5 with 
CSD larger than 1.0 ppm). Residues of I28, G29, and V31 were located on the D β-strand, 
E33 was located in the D-E loop, T40 was located in the E β-strand,  T75 was located in 
the G β-strand, D122, E127, R133, and K136 were located in the J-K loop, N138 was 
located in the K β-strand and A164 was located in the M β-strand.  
Previous data showed that D-E and J-K loops are the key components of the high 
affinity ephrin binding channel of the Eph receptors (Himanen et al. 2009; Qin et al. 
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2008). Therefore, the NMR titration results suggested that WDC probably bound to the 





Figure 23: Residue-specific CSD of the EphA5 ligand-binding domain in the 




Chapter IV CONCLUSION AND FUTURE WORK 
 
The crystal of the EphA5 ligand-binding domain was obtained. Its crystal structure 
showed a high degree of similarity to the previously determined ligand-binding domains 
of the Eph A and B receptors. EphA5 adopts the conserved jellyroll folding architecture 
and a compact β-sandwich.  
The CD and NMR data showed that free WDC existed in a well-folded structure 
consisted of β-turns in solution. Residues Gly6 and Pro7 presented in the 4-residue ring 
formed by Cys5-Cys10 contributed to the formation of turn structure in the peptide.  
In conclusion, EphA5 and WDC possessed medium binding activity according to 
the NMR and ITC data. The residues of WDC involved in the interaction with EphA5 
were mapped by NMR titration and Ala site-directed mutagenesis methods. Moreover, 
the binding surface of EphA5 to WDC was determined by chemical shift perturbation 
analysis from NMR titration data. 
Taken all together, our results may provide critical rationales for further design of 
specific EphA5 antagonists for various therapeutic applications. To better understand the 
binding interface between EphA5 and WDC, it will be necessary to co-crystalize the 
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Figure 1: Sequence alignment of the ligand-binding domains of EphA5 with 
EphA2 and EphB2. The identical residues are colored in blue, and the homological 
residues are colored in light blue.  
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Table 1: 15N, 15NH and 13C chemical shift of EphA5 at pH 6.3 and 25°C   
 
NO Residue N NH Cα Cβ 
1 Asn 119.959 8.684 54.022 38.528 
2 Glu 119.037 7.792 55.181 30.884 
3 Val 125.764 8.744 61.734 32.18 
4 Asn 123.852 8.659 54.226 38.596 
5 Leu 124.696 9.798 55.307 43.571 
6 Leu   55.945 45.632 
7 Asp 126.748 8.943 54.158 42.145 
8 Ser 122.478 9.326 62.758 63.441 
9 Arg 119.735 8.566 58.458 30.747 
10 Thr 106.23 7.696 61.256 69.515 
11 Val 123.374 7.059 63.577 32.317 
12 Met 128.295 8.711 55.523 32.454 
13 Gly 111.328 8.076 44.603  
14 Asp 118.997 8.045 54.431 41.804 
15 Leu 125.55 8.847 57.434 41.394 
16 Gly 105.746 8.522 46.513  
17 Trp 122.331 7.629 55.796 29.45 
18 Ile 121.103 9.058 61.12 41.258 
19 Ala 130.088 8.423 50.609 22.556 
20 Phe 121.469 8.553 54.636 41.258 
21 Pro   63.372 35.457 
22 Lys 121.558 9.029 58.799 32.522 
23 Asn 114.928 8.166 52.861 37.095 
24 Gly 106.72 7.333 45.08  
25 Trp 127.291 8.602 58.731 30.542 
26 Glu 120.771 9.074 55.318 34.296 
27 Glu 126.269 8.806 55.864 29.86 
28 Ile 126.941 8.393 60.779 39.824 
29 Gly 115.494 8.651 46.036  
30 Glu 123 8.187 55.25 32.726 
31 Val 117.525 8.321 60.799 34.638 
32 Asp 122.638 8.449 52.861 41.736 
33 Glu 118.368 9.044 58.458 28.972 
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34 Asn 118.022 8.315 53.339 39.347 
35 Tyr 116.323 8.061 59.686 36.07 
36 Ala 125.463 8.306 50.131 18.871 
37 Pro     
38 Ile   60.642 43.578 
39 His 122.512 9.031 55.523 28.7 
40 Thr 114.762 7.696 61.393 71.358 
41 Tyr   57.843 43.715 
42 Gln 120.557 9.532 54.363 33.136 
43 Val 122.249 8.359 61.666 34.911 
44 Cys 128.779 8.652 58.731 46.377 
45 Lys 130.822 9.813 55.523 30.201 
46 Val   62.963 31.975 
47 Met 116.992 8.384 55.523 31.566 
48 Glu 120.231 7.551 55.659 32.18 
49 Gln 118.896 8.469 55.933 30.815 
50 Asn 117.079 8.945 54.294 37.573 
51 Gln 118.06 8.721 56.137 29.109 
52 Asn 122.683 8.7 53.066 38.255 
53 Asn 119.685 9.28 53.953 41.395 
54 Trp 128.191 9.852 57.98 31.703 
55 Leu 127.494 8.831 54.021 44.398 
56 Leu 129.631 9.434 53.68 46.172 
57 Thr 111.731 8.265 62.553 71.631 
58 Ser   57.98 64.669 
59 Trp 121.983 8.498 60.3 28.29 
60 Ile 131.381 7.917 60.232 38.074 
61 Ser 118.983 7.601 57.366 63.918 
62 Asn 120.551 8.026 52.52 39.347 
63 Glu 113.337 8.19 57.956 27.881 
64 Gly 106.238 8.54 45.217  
65 Ala 125.313 7.836 52.657 18.871 
66 Ser 113.332 8.19 58.731 64.669 
67 Arg 121.327 7.404 55.25 32.521 
68 Ile 119.288 8.143 58.116 42.145 
69 Phe 120.461 8.962 56.615 40.712 
70 Ile 120.577 9.053 60.779 42.009 
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71 Glu   54.908 34.569 
72 Leu 130.41 9.806 53.27 46.241 
73 Lys 119.966 8.896 55.387 34.569 
74 Phe 119.865 8.805 56 42.76 
75 Thr 113.411 9.487 60.301 71.289 
76 Leu 125.483 8.918 54.635 46.172 
77 Arg 124.776 8.046 55.796 31.839 
78 Asp 122.631 8.365 54.226 41.462 
79 Cys 125.218 9.63 58.526 39.688 
80 Asn 117.978 8.781 55.318 38.255 
81 Ser 114.223 7.941 58.799 64.464 
82 Leu 125.373 7.375 52.998 42.623 
83 Pro   63.85 31.907 
84 Gly 109.036 8.387 45.626  
85 Gly 108.364 8.198 45.831  
86 Leu 121.691 8.087 56.137 42.419 
87 Gly 109.879 8.524 45.968  
88 Thr 112.663 7.849 62.076 69.856 
89 Cys 123.352 8.116 57.843 40.439 
90 Lys 129.386 8.552 54.499 35.388 
91 Glu 117.616 8.64 55.181 30.065 
92 Thr 106.977 6.997 59.345 72.791 
93 Phe 113.535 8.306 57.161 40.712 
94 Asn 115.741 8.762 52.452 43.374 
95 Met 120.549 8.026 54.84 36.89 
96 Tyr 126.059 9.507 56.752 44.739 
97 Tyr 116.529 9.587 56.478 43.169 
98 Phe 115.989 8.336 57.57 42.555 
99 Glu 124.01 8.946 57.161 32.795 
100 Ser 112.9 8.421 58.321 66.102 
101 Asp 127.842 9.261 55.864 41.394 
102 Asp 119.518 8.364 53.202 42.213 
103 Gln 122.379 8.084 56.751 27.812 
104 Asn 119.175 8.264 52.929 39.074 
105 Gly 110.537 8.207 46.855  
106 Arg 118.971 7.945 56.888 30.201 
107 Asn 117.617 7.915 52.929 38.459 
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108 Ile 121.361 7.266 61.529 38.119 
109 Lys 125.514 7.939 55.933 32.999 
110 Glu 119.531 8.068 58.321 29.655 
111 Asn 114.515 7.525 53.885 37.846 
112 Gln 118.619 7.768 55.864 29.655 
113 Tyr   58.867 39.074 
114 Ile 124.255 9.194 60.847 38.46 
115 Lys 129.527 9.055 58.594 32.931 
116 Ile 128.282 9.329 63.577 39.074 
117 Asp 110.272 7.268 53.134 43.783 
118 Thr 119.955 8.684 63.031 70.675 
119 Ile 129.527 9.055 58.868 35.388 
120 Ala 127.812 8.047 49.926 23.444 
121 Ala 121.94 8.83 52.178 20.099 
122 Asp 123.345 8.398 53.885 42.146 
123 Glu 119.976 8.51 57.229 30.201 
124 Ser 117.002 8.236 57.98 63.713 
125 Phe 121.333 7.958 56.956 40.985 
126 Thr 114.572 8.557 61.393 71.221 
127 Glu 123.159 8.586 56.342 31.293 
128 Leu     
129 Asp     
130 Leu   54.772 42.077 
131 Gly 111.413 8.679 46.718  
132 Asp 120.53 8.284 54.226 40.985 
133 Arg 125.568 8.376 56.547 33.204 
134 Val   61.597 33.613 
135 Met 124.85 8.71 54.841 35.525 
136 Lys 124.719 8.429 56.137 32.794 
137 Leu 125.761 8.744 54.363 43.784 
138 Asn 126.109 8.714 53.885 41.326 
139 Thr 117.153 8.522 61.87 71.221 
140 Glu 124.849 9.111 54.841 34.842 
141 Val 122.512 8.823 60.3 34.978 
142 Arg 126.748 8.943 53.271 34.774 
143 Asp 118.17 8.18 52.247 44.193 
144 Val 116.007 8.257 60.301 35.934 
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145 Gly 109.427 7.672 44.671  
146 Pro   61.324 34.16 
147 Leu 126.194 8.888 54.772 41.559 
148 Ser   59.55 66.034 
149 Lys 122.962 7.58 55.045 33.409 
150 Lys 118.053 9.463 58.662 33.818 
151 Gly 130.857 7.411 46.309  
152 Phe 118.571 8.142 56.206 40.712 
153 Tyr 115.676 8.807 56.956 42.691 
154 Leu 118.685 7.806 53.407 42.555 
155 Ala 121.205 8.181 49.926 24.126 
156 Phe 120.124 9.327 56.069 42.009 
157 Gln 123.43 9.184 53.749 32.112 
158 Asp 128.803 9.583 52.042 46.309 
159 Val 118.004 9.297 59.687 31.157 
160 Gly 112.861 8.495 47.078  
161 Ala   50.336 23.103 
162 Cys 121.769 9.177 56.274 45.899 
163 Ile 126.513 8.966 60.437 43.442 
164 Ala 127.228 8.498 51.974 20.236 
165 Leu 127.047 9.757 54.568 42.965 
166 Val 126.465 8.483 64.191 32.863 
167 Ser 110.922 8.052 58.867 65.079 
168 Val 125.797 8.794 62.485 35.593 
169 Arg 129.242 9.121 54.704 35.457 
170 Val 127.525 9.6 60.096 34.16 
171 Tyr 125.906 9.557 56.137 42.009 
172 Tyr 115.677 8.807 55.523 42.077 
173 Lys 120.114 9.245 55.591 34.774 
174 Glu 123.738 8.484 56.342 31.498 
175 Ala 127.05 8.566 50.677 18.666 
176 Pro   63.508 32.249 
177 Ser 121.865 7.961 60.164 65.215 
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Table 2: 15N, 15NH and 13C chemical shift of EphA5 in the presence of 3-fold 
WDC at pH 6.3 and 25°C   
NO Residue N NH Cα Cβ 
1 Asn 119.777 8.683 53.963 38.538 
2 Glu 118.825 7.782 55.26 30.825 
3 Val 125.535 8.736 61.813 32.122 
4 Asn 123.61 8.655 54.236 38.538 
5 Leu 124.49 9.801 55.397 43.589 
6 Leu   55.874 45.432 
7 Asp 126.327 8.994 54.168 42.292 
8 Ser 122.301 9.41 62.427 63.451 
9 Arg 120.785 8.537 58.673 31.098 
10 Thr 106.059 7.624 61.266 69.525 
11 Val 123.141 7.021 63.605 32.413 
12 Met 127.503 8.675 55.397 32.344 
13 Gly 111.811 8.058 44.544  
14 Asp 118.364 7.933 54.441 41.2 
15 Leu 125.719 9.564 57.444 40.859 
16 Gly 105.276 8.642 46.797  
17 Trp 121.9 7.486 55.601 29.119 
18 Ile 121.252 9.013 61.198 40.381 
19 Ala 130.377 8.447 50.687 22.362 
20 Phe 121.458 8.537 54.578 41.336 
21 Pro   63.382 35.398 
22 Lys 121.374 9.037 58.741 32.532 
23 Asn 114.913 8.173 52.803 36.968 
24 Gly 106.373 7.282 45.227  
25 Trp 126.798 8.636 58.895 30.621 
26 Glu 121.034 8.821 55.465 33.829 
27 Glu 126.478 8.782 55.738 28.846 
28 Ile 129.644 8.523 58.946 40.244 
29 Gly 119.315 8.64 46.251  
30 Glu 123.505 8.334 54.168 34.306 
31 Val 115.207 9.078 59.697 33.76 
32 Asp 121.153 8.266 51.643 41.354 
33 Glu 115.979 10.46 58.468 27.686 
34 Asn 119.907 8.441 53.417 39.289 
35 Tyr 116.222 8.413 61.13 34.033 
36 Ala 124.817 8.405 49.663 18.881 
37 Pro   62.836 32.19 
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38 Ile 119.618 8.963 60.447 43.043 
39 His 122.579 8.976 55.738 29.392 
40 Thr 111.174 7.319 59.628 72.1 
41 Tyr 118.55 8.304 59.059 43.794 
42 Gln 120.917 9.372 54.373 31.917 
43 Val 124.293 9.027 61.608 35.535 
44 Cys 127.703 8.644 58.809 46.66 
45 Lys 130.058 9.693 55.738 30.211 
46 Val 109.071 6.466 63.246 32.122 
47 Met 116.832 8.414 55.892 31.321 
48 Glu 120.037 7.633 55.601 31.849 
49 Gln 118.555 8.43 56.079 30.638 
50 Asn 116.945 8.924 54.254 37.6 
51 Gln 117.911 8.718 56.147 29.187 
52 Asn 122.517 8.714 53.076 38.283 
53 Asn 119.618 9.271 54.1 41.366 
54 Trp 127.805 9.8 58.127 31.781 
55 Leu 127.289 8.829 54.236 44.817 
56 Leu 129.661 9.474 53.64 46.268 
57 Thr 111.978 8.303 62.563 71.709 
58 Ser 108.546 6.187 58.263 64.543 
59 Trp 121.837 8.49 60.243 28.232 
60 Ile 131.11 7.875 59.987 38.965 
61 Ser 118.79 7.575 57.257 63.878 
62 Asn 120.321 8.046 53.827 39.17 
63 Glu 113.306 8.174 56.967 27.891 
64 Gly 106.059 8.534 45.295  
65 Ala 125.05 7.831 52.53 18.881 
66 Ser 113.043 8.175 58.673 64.747 
67 Arg 121.157 7.409 55.328 32.6 
68 Ile 119.203 8.148 58.195 41.951 
69 Phe 120.288 8.961 56.762 40.79 
70 Ile 120.361 9.053 60.857 41.882 
71 Glu 127.625 10 54.919 34.306 
72 Leu 130.075 9.824 53.213 46.114 
73 Lys 119.975 8.912 55.328 33.897 
74 Phe 119.164 8.788 55.806 42.292 
75 Thr 117.286 9.033 60.106 70.958 
76 Leu 124.361 8.356 54.509 46.114 
77 Arg 123.012 8.492 55.533 32.122 
78 Asp 122.983 8.361 54.236 41.405 
79 Cys 123.885 9.667 58.673 39.494 
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80 Asn 117.382 8.726 55.192 37.992 
81 Ser 114.434 7.924 58.809 64.611 
82 Leu 124.891 7.33 52.94 42.497 
83 Pro   63.665 31.986 
84 Gly 108.572 8.346 45.705  
85 Gly 108.199 8.2 45.841  
86 Leu 121.314 8.087 56.011 42.565 
87 Gly 109.38 8.474 45.978  
88 Thr 112.683 7.862 61.949 70.003 
89 Cys 123.243 8.123 58.059 40.654 
90 Lys 129.133 8.509 54.646 35.398 
91 Glu 117.584 8.656 55.055 30.006 
92 Thr 106.715 6.969 59.219 72.6 
93 Phe 113.144 8.174 57.035 40.244 
94 Asn 115.908 8.844 52.394 43.248 
95 Met 120.429 8.048 54.782 36.832 
96 Tyr 126.079 9.525 56.711 44.767 
97 Tyr 116.333 9.587 56.574 43.06 
98 Phe 115.529 8.3 57.581 42.429 
99 Glu 123.602 8.977 57.2 32.822 
100 Ser 112.826 8.435 58.468 66.112 
101 Asp 127.667 9.255 55.755 41.559 
102 Asp 119.295 8.331 53.367 42.31 
103 Gln 122.06 8.068 56.847 27.84 
104 Asn 118.942 8.237 52.957 39.152 
105 Gly 110.368 8.254 46.951  
106 Arg 118.766 7.955 56.83 30.279 
107 Asn 117.397 7.947 53.008 38.538 
108 Ile     
109 Lys     
110 Glu     
111 Asn     
112 Gln     
113 Tyr   58.922 39.153 
114 Ile 123.044 8.263 60.652 38.66 
115 Lys 129.366 9.068 58.622 32.822 
116 Ile 128.038 9.325 63.86 38.948 
117 Asp 109.87 7.277 53.23 43.606 
118 Thr 119.912 8.645 63.314 70.412 
119 Ile 129.181 9.112 58.946 34.921 
120 Ala 127.235 7.891 49.663 23.522 
121 Ala 122.579 8.976 52.735 18.881 
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122 Asp 125.899 8.665 54.305 42.292 
123 Glu 120.283 8.679 58.195 30.484 
124 Ser 115.519 8.313 57.325 63.059 
125 Phe 121.332 7.587 56.42 40.859 
126 Thr 114.675 8.695 60.925 71.573 
127 Glu 125.998 8.836 55.874 30.689 
128 Leu 127.051 9.082 54.236 43.521 
129 Asp 123.36 8.7 53.963 40.586 
130 Leu 126.418 8.407 53.349 40.927 
131 Gly 112.485 8.792 47.07  
132 Asp 121.607 8.376 54.236 40.79 
133 Arg 115.799 7.346 54.527 32.959 
134 Val 117.15 8.187 60.328 35.006 
135 Met 124.76 8.627 54.782 38.897 
136 Lys 127.827 8.929 56.83 33.146 
137 Leu   53.895 44.681 
138 Asn 128.872 8.907 54.236 41.268 
139 Thr 116.292 8.149 61.881 71.3 
140 Glu 124.671 9.2 54.919 35.194 
141 Val 122.132 8.799 60.243 35.125 
142 Arg 126.248 8.915 53.213 34.921 
143 Asp 117.852 8.169 52.325 44.271 
144 Val 115.63 8.254 60.243 35.944 
145 Gly 109.207 7.667 44.613  
146 Pro   61.216 33.983 
147 Leu 125.931 8.883 54.646 41.678 
148 Ser 117.089 10.267 59.765 66.181 
149 Lys 122.761 7.585 55.124 33.146 
150 Lys 117.885 9.471 58.554 33.778 
151 Gly 133.662 7.403 46.319  
152 Phe 118.415 8.153 56.079 40.654 
153 Tyr 115.368 8.721 56.967 42.77 
154 Leu 118.403 7.734 53.349 44.749 
155 Ala 120.985 8.199 49.868 24.205 
156 Phe 119.666 9.387 55.874 42.156 
157 Gln 123.038 9.209 53.776 32.276 
158 Asp 128.759 9.619 51.984 45.909 
159 Val 117.818 9.218 59.697 30.962 
160 Gly 112.744 8.543 46.865  
161 Ala 128.163 9.996 50.414 23.045 
162 Cys 122.484 9.231 56.284 46.592 
163 Ile 124.846 9.243 60.192 43.606 
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164 Ala 124.538 7.945 50.551 18.403 
165 Leu 127.045 9.613 54.782 42.975 
166 Val 124.995 8.456 64.27 32.6 
167 Ser 109.547 7.97 59.151 65.293 
168 Val 123.624 8.827 62.359 36.217 
169 Arg 129.38 9.173 54.987 35.33 
170 Val 127.327 9.604 60.124 34.119 
171 Tyr 125.719 9.564 56.097 42.036 
172 Tyr 115.442 8.798 55.414 42.036 
173 Lys 119.913 9.252 55.601 34.784 
174 Glu 123.536 8.482 56.489 31.508 
175 Ala 126.867 8.563 50.687 18.676 
176 Pro   63.468 32.208 
177 Ser 121.631 7.957 60.174 65.225 
 
 
 
 
